• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now

    10/3/23 7:00:00 AM ET
    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGBA alert in real time by email

    MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 1

    October 4, 2023

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    AGBA Group Holding Limited (NASDAQ:AGBA)

    Mr. Wing-Fai Ng, Group President of AGBA Group

    9:40 - 10:10

    Loop Industries, Inc. (NASDAQ:LOOP)

    Kevin C. O'Dowd, VP Communications

    10:15 - 10:45

    CoTec Holdings Corp. (OTCQB:CTHCF) (TSXV:CTH)

    Julian Treger, President / CEO

    10:50 - 11:20

    ASP Isotopes, Inc. (NASDAQ:ASPI)

    Paul Elliot Mann, CEO

    11:25 - 11:55

    Akari Therapeutics, plc (NASDAQ:AKTX)

    Rachelle Jacques, CEO

    12:00 - 12:30

    FendX Technologies, Inc. (OTCQB:FDXTF) (CSE:FNDX)

    Carolyn Jane Myers, CEO

    1:10 - 1:40

    NeuroSense Therapeutics, Ltd. (NASDAQ:NRSN)

    Alon Ben-Noon, Co-Founder, CEO & Director

    Postponed to November 1, 2023

    Coeptis Therapeutics Holdings, Inc., (NASDAQ:COEP)

    David Mehalick, President / CEO

    2:55 - 3:05

    Rakovina Therapeutics Inc. (TSXV:RKV)

    Jeffrey Bacha, Executive Chairman & David Hyman, President

    3:10 - 3:20

    Alpha Tau Medical, Inc. (NASDAQ:DRTS)

    Raphi Levy, CFO

    3:25 - 3:35

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    David Dodd, Chairman, President / CEO

    3:40 - 3:50

    Renforth Resources, Inc. (OTCQB:RFHRF) (CSE:RFR)

    Nicole Brewster, President & CEO

    3:55 - 4:05

    NeuroMetrix, Inc. (NASDAQ:NURO)

    Dr. Shai Gozani, CEO & Thomas Higgins, CFO

    Day 2

    October 5, 2023

    9:00

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:35

    Introduction

    9:40 - 10:10

    Theriva Biologics (NYSE:TOVX)

    Steven A. Shallcross, CEO / CFO

    10:15 - 10:45

    Bioxytran, Inc. (OTCQB:BIXT)

    Mike Sheikh, Executive Vice President Business Development

    10:50 - 11:20

    Inspire Veterinary Partners, Inc. (NASDAQ:IVP)

    Kimball Carr, Chairman, President & CEO

    12:00 - 12:30

    BioLargo, Inc. (OTCQB:BLGO)

    Dennis Calvert, President / CEO

    1:10 - 1:40

    Nextech3D.ai, formerly known as "Nextech AR Solutions Corp" (OTCQX:NEXCF) (CSE:NTAR) (FSE: EP2)

    Evan Gappelberg, CEO

    1:45 - 2:15

    Sokoman Minerals Corp., (OTCQB:SICNF) (TSXV:SIC)

    Timothy Froude P. Geo. CEO, Pres & Director

    2:20 - 2:50

    Knightscope, Inc. (NASDAQ:KSCP) 

    William Santana Li Chairman & CEO

    2:55 - 3:05

    Cyngn, Inc. (NASDAQ:CYN)

    Lior Tal, CEO & Director

    3:10 - 3:20

    Citizens, Inc. (NYSE:CIA)

    Gerald W. Shields, Vice Chairman / CEO, & Jeff Conklin, CFO

    3:25 - 3:35

    Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE)

    Michael Martino, CEO & Director

    3:40 - 3:50

    Steppe Gold, Ltd. (OTCQX:STPGF) (TSX:STGO)

    Aneel Singh, Exec. VP & Director

    3:55 – 4:05

    Regen Biopharma, Inc. (OTC:RGBP)

    David Koos, President / CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AGBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGBA
    $AKTX
    $AMPE
    $ASPI

    CompanyDatePrice TargetRatingAnalyst
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Akari Therapeutics plc
    $AKTX
    1/5/2026$1.00Buy
    Ladenburg Thalmann
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Akari Therapeutics plc
    $AKTX
    7/18/2025$5.00Buy
    Maxim Group
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    Knightscope Inc.
    $KSCP
    1/30/2025$16.00Buy
    H.C. Wainwright
    More analyst ratings

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stenberg Jon

    4 - CITIZENS, INC. (0000024090) (Issuer)

    3/20/26 4:05:02 PM ET
    $CIA
    Life Insurance
    Finance

    SEC Form 4 filed by Stenberg Jon

    4 - CITIZENS, INC. (0000024090) (Issuer)

    3/19/26 3:15:25 PM ET
    $CIA
    Life Insurance
    Finance

    SEC Form 3 filed by new insider Avruch Michael

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:04:47 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Akari Therapeutics with a new price target

    Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00

    1/5/26 8:57:02 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    SEC Filings

    View All

    SEC Form 10-K filed by Coeptis Therapeutics Holdings Inc.

    10-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

    3/19/26 5:00:29 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akari Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Akari Therapeutics Plc (0001541157) (Filer)

    3/17/26 5:07:26 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyngn Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Cyngn Inc. (0001874097) (Filer)

    3/17/26 4:30:26 PM ET
    $CYN
    EDP Services
    Technology

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- Cyngn/

    In the news release, At GTC, Cyngn Advances High-Fidelity Forklift Simulation Through FMU Integration in NVIDIA Isaac Sim, issued 16-Mar-2026 by Cyngn over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: At GTC, Cyngn Advances High-Fidelity Forklift Simulation Through FMU Integration in NVIDIA Isaac Sim MOUNTAIN VIEW, Calif., March 16, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) announced it is integrating its high-fidelity forklift vehicle models into NVIDIA Isaac Sim, an open simulation framework for developing autonomous systems.

    3/16/26 7:10:00 AM ET
    $CYN
    EDP Services
    Technology

    /C O R R E C T I O N -- NeuroSense/

    In the news release, PrimeC New Data to Be Presented at AD/PD™ 2026 Conference, issued 18-Mar-2026 by NeuroSense over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: PrimeC New Data to Be Presented at AD/PD™ 2026 Conference Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announ

    3/18/26 8:00:00 AM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

    TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulne

    3/18/26 8:05:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hart Spencer bought $66,070 worth of shares (50,000 units at $1.32), increasing direct ownership by 14% to 410,370 units (SEC Form 4)

    4 - Loop Industries, Inc. (0001504678) (Issuer)

    11/12/25 4:33:21 PM ET
    $LOOP
    Major Chemicals
    Industrials

    CEO Gaslightwala Abizer bought $19,540 worth of American Depositary Shares representing Ordinary Shares (21,000 units at $0.93), increasing direct ownership by 8% to 298,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    8/29/25 4:55:12 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Financials

    Live finance-specific insights

    View All

    Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

    - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

    3/12/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyngn Announces Date for 2025 Fourth Quarter and Year-End Financial Results

    MOUNTAIN VIEW, Calif., March 5, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its 2025 fourth quarter and year-end financial results for the period ended December 31, 2025, on Wednesday, March 25, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges f

    3/5/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    Cyngn Reports Third Quarter 2025 Financial Results

    Recent Operating Highlights Deployed the DriveMod Tugger at G&J Pepsi, the Largest Independent Pepsi Bottler in the USAU.S. Continental "definitely recommends" the DriveMod Tugger.Secured funding that extends Cyngn's cash runway through 2027, reinforcing balance-sheet stability and capacity to scale operations.Appointed Natalie Russell as Chief Financial Officer to strengthen financial leadership and operational discipline.Expanded the sales organization to the largest in company history, reflecting a more mature commercial posture.Deployed the DriveMod Tugger at Coats, marking another live industrial implementation of Cyngn's autonomous vehicle technology.Secured Cyngn's 23rd U.S. patent, c

    11/18/25 5:41:00 PM ET
    $CYN
    EDP Services
    Technology

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGBA
    $AKTX
    $AMPE
    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer

    DALLAS, March 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has appointed Nate Salpeter, Ph.D. as its Chief Technology Officer. Dr. Salpeter is a recognized key opinion leader in the field of physics-constrained energy technology optimization, with more than 15 years of experience building computational frameworks, laser-based experimental methods, and first-of-kind engineering programs across nuclear energy and advanced thermal sys

    3/5/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology